Anti-TROP2 monoclonal antibody for ADC
Product | Unit size | Cat. code | Docs. | Qty. | Price | |
---|---|---|---|---|---|---|
Anti-TROP2-hIgG1 TROP2 antibody for conjugation assays - Human IgG1 |
Show product |
1 mg |
trop2-mab1-1
|
|
Monoclonal human IgG1 antibody against TROP2 for antibody-drug conjugation
InvivoGen provides Anti-TROP2-hIgG1, a monoclonal antibody (mAb) specifically developed for the generation of antibody-drug conjugates (ADCs). This mAb features:
Anti-TROP2 PRR ligand bioconjugation
(click to enlarge)
- the variable region of sacituzumab, which specifically targets the human trophoblast cell-surface antigen 2 (TROP2),
- a human IgG1 constant region that displays high effector functions, including antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).
InvivoGen's Anti-TROP2-hIgG1 has been generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography.
TROP2 background
TROP2 (trophoblast cell-surface antigen 2), also known as TACD2 (tumor-associated calcium signal transducer 2), is a transmembrane protein expressed in normal human tissues, including breast, cervix, kidney, lung, and pancreas, and is upregulated in most tumors of epithelial origin [1]. TROP2 plays an important role in embryonic development and is implicated in several oncogenetic signaling pathways leading to proliferation [1].
One therapeutic strategy aiming at killing TROP2+ cancer cells, notably in triple-negative breast cancer patients, uses the FDA-approved antibody-drug conjugate (ADC) Trodelvy [2,3]. It consists of the combination of the Anti-TROP2 sacituzumab and the SN-38 cytotoxic payload [2,3]. This ADC allows targeted drug delivery to cancer cells in addition to the mAb-mediated effector functions [2,3]. Other TROP2-targeting ADCs featuring different cytotoxic cargos have been developed and have progressed to human clinical trials [4].
Anti-TROP2 ADC modes of action
(click to enlarge)
In a co-culture of TROP2+ tumor cells and human peripheral blood monocytes (PBMCs), ADCs combining InvivoGen's Anti-TROP2-hIgG1 and STING or TLR7 agonists induce a significantly higher production of IL-6 and CXCL10 pro-inflammatory cytokines than unconjugated agonists or negative control ADCs (see Figures).
Key features of Anti-TROP2-hIgG1
- Clinically-relevant variable region targeting human TROP2 (sacituzumab)
- Human IgG1 constant region for high effector functions
- Functionally validated by flow cytometry and ADC-based cellular assays
- The absence of bacterial contamination has been confirmed
InvivoGen offers conjugatable PRR ligands for building immunostimulatory Anti-TROP2 ADCs.
You may choose from TLR7 and STING agonists:
- Conjugatable TLR7 agonists: TL7-887 and TL7-975
- Conjugatable STING agonists: STG-982 and STG-968
Learn more about bioconjugation
InvivoGen’s products are for research use only, and not for clinical or veterinary use.
References
1. Trerotola, M., et al., 2013. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene 32, 222–233.
2. Drago J.Z. et al., 2021. Unlocking the potential of antibody–drug conjugates for cancer therapy. Nat Rev Clin Oncol. 18-6):327.
3. Tarantino P. et al., 2022. Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 72:165-182.
4. Shaffer, C. 2021. Trop2 deal heats up antibody–drug conjugate space in cancer. Nat Biotechnol 39, 128–130.
Specifications
Specificity: Targets cells expressing TROP2
Variable region biosimilar: Sacituzumab
Isotype: Human IgG1, Kappa
Source: Chinese hamster ovary (CHO) cells
Formulation: 0.2 μm filtered solution in 150 mM sodium chloride, 20 mM sodium phosphate buffer with 5% saccharose
Purification: Affinity chromatography with protein A
Tested Applications: Flow cytometry, ELISA, Antibody-drug conjugation
Quality control:
- The binding of Anti-TROP2-hIgG1 mAb to TROP2 has been validated using flow cytometry, ELISA, and antibody-drug conjugate (ADC)-based cellular assays.
- The complete sequence of the antibody has been verified.
- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ hTLR2 and HEK-Blue™ TLR4 cellular assays.
Contents
- 1 mg of purified Anti-TROP2-hIgG1 monoclonal antibody (mAb), provided azide-free and lyophilized
The product is shipped at room temperature.
Store lyophilized antibody at -20 °C.
Lyophilized product is stable for at least 1 year. Reconstituted antibody is stable for 1 month at 4°C and for 1 year at -20°C. Avoid repeated freeze-thaw cycles.
Tags: buy Sacituzumab (anti-TROP2) | Sacituzumab (anti-TROP2) supplier | purchase Sacituzumab (anti-TROP2) | Sacituzumab (anti-TROP2) cost | Sacituzumab (anti-TROP2) manufacturer | order Sacituzumab (anti-TROP2) | Sacituzumab (anti-TROP2) distributor
Back to the top